Intervention

Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

1 shown

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.NCT06973525 · 2025-09-01

NOT_YET_RECRUITING

Common conditions

HER2-positive Breast Cancer1

Leading sponsors

Hebei Medical University Fourth Hospital1

Trial status mix

NOT_YET_RECRUITING1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.